VJHemOnc is committed to improving our service to you

SOHO 2020 | Changing treatment landscape of relapsed/refractory myeloma

VJHemOnc is committed to improving our service to you

Joshua Richter

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, outlines the changing treatment landscape for patients with relapsed/refractory multiple myeloma including the approval of belantamab mafodotin, a BCMA targeting antibody-drug conjugate, as well as melflufen, evaluated in the HORIZON (NCT02963493) and OCEAN (NCT03151811) trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter